Physiological properties and characteristic reactions of hydroxyurea
As it was mentioned in the previous paper, we observed the mechanism of action the interesting drug, first synthesized back in 1869 for the first time, called Hydroxyurea. A century later, phase I and II trials began to test its safety in humans with solid tumors. It was first approved by the FDA in 1967 for the treatment of neoplastic diseases and is presently approved for the treatment of melanoma, resistant chronic myelocytic leukemia (CML), and recurrent, metastatic testicular and ovarian cancer. Sickle cell disease is a genetic disorder that decreases life expectancy by 25 to 30 years. Individuals are diagnosed with sickle cell disease if they have one of several genotypes that result in at least half of their hemoglobin being hemoglobin S (HbS). Sickle cell anemia refers specifically to the condition associated with homozygosity for the Hb S mutation (Hb SS). Several other hemoglobin mutations, when occurring with an Hb S mutation, cause a similar but often milder disease than sickle cell anemia. In addition to reduced life expectancy, patients with sickle cell disease experience chronic pain and reduced quality of life. Painful crises, also known as vaso-occlusive crises, are the most common reason for emergency department use and hospitalization, and acute chest syndrome is the most common cause of death. Prior to the approval of hydroxyurea for use in sickle cell disease, patients with this condition were treated only with supportive therapies. These measures included penicillin in children to prevent pneumococcal disease, routine immunizations, and hydration and narcotic therapy to treat painful events. Red blood cell transfusions increase the blood’s oxygen carrying capacity and decrease the concentration of cells with abnormal hemoglobin, but chronic transfusion therapy predictably leads to iron overload and alloimmunization. Therapies such as hydroxyurea that raise fetal hemoglobin (Hb F, α2γ2) levels are promising because they effectively lower the concentration of Hb S within a cell, resulting in less polymerization of the abnormal hemoglobin.Hydroxyurea’s efficacy in sickle cell disease is generally attributed to its ability to raise the levels of Hb F in the blood; however, the mechanisms by which it does so are unclear. Early studies suggested that hydroxyurea is cytotoxic to the more rapidly dividing late erythroid precursors, resulting in the recruitment of early erythroid precursors with an increased capacity to produce HbF.
Alvarez-Larrán, A., Díaz-González, A., Such, E. et al. (2010). Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. Leukemia, 2020. doi: 10.1038/s41375-020-0849-2.
Boyd, A. S., & Neldner, K. H. (1991). Hydroxyurea therapy. Journal of the American Academy of Dermatology, 25(3), 518–524.
Charache, S., Terrin, M. L., & Moore, R. D. (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med, 332(20), 1317–1322. doi: 10.1056/NEJM199505183322001.
Cheng, Z.-P., Chu, X.-Z., Wu, X.-Q., Xu, J.-M., Zhong, H., & Yin, J.-Z. (2017). Controlled synthesis of silver nanoplates and nanoparticles by reducing silver nitrate with hydroxylamine hydrochloride. Rare Metals, 36(10), 799–805. doi: 10.1007/s12598-017-0949-y.
Davies, B. W., Kohanski, M. A., Simmons, L. A., Winkler, J. A., Collins, J. J., & Walker, G. C. (2009). Hydroxyurea induces hydroxyl radical-mediated cell death in Escherichia coli. Molecular cell, 36(5), 845–860. doi: 10.1016/j.molcel.2009.11.024.
Donehower, R. C. (1992). An overview of the clinical experience with hydroxyurea. Seminars in Oncology, 19(9), 11–19. URL: https://pubmed.ncbi.nlm.nih.gov/ 1641651.
Dresler, W. F. C., & Stein, R. (1869). Ueber den Hydro-xylharnstoff; Annalen Der Chemie Und Pharmacie, 150(2), 242–252. doi: 10.1002/jlac.18691500212.
Faygl, F. (1962). Kapelnyiy analiz organicheskih veschestv. M. (in Russian).
Frimantl, M. (1991). Himiya v deystvii, tom 2, izd. “Mir”, M. (in Russian).
Gibbs, M. A., & Sorensen, S. J. (2000). Hydroxyurea in the treatment of HIV-1. Annals of Pharmacotherapy, 34(1), 89–93. doi: 10.1345/aph.19004.
Gwilt, P. R., & Tracewell, W. G. (1998). Pharmacokinetics and Pharmacodynamics of Hydroxyurea. Clin Pharmacokinet, 34, 347–358. doi: 10.2165/00003088-199834050-00002.
Kennedy, B. J. (1972). Hydroxyurea therapy in chronic myelogenous leukemia. Cancer, 29(4), 1052–1056. doi: 10.1002/1097-0142(197204)29:1<1052::AID-CNCR2820290454>3.0.CO;2-7.
King, S. B. (2004). Nitric oxide production from hydroxyurea. Free Radical Biology and Medicine, 37(6), 737–744. doi: 10.1016/j.freeradbiomed.2004.02.073.
Lange, T., Niederwieser, C., Gil, A., Krahl, R., von Grünhagen, U., Al-Ali, H. K., & Junghanss, C. (2020). No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group. Leukemia & Lymphoma, 1–10. doi: 10.1080/10428194.2020.1786556.
Lanzkron, S., Strouse, J. J., Wilson, R., Beach, M. C., Haywood, C., Park, H., Witkop, C., Eric, E. B., & Segal, J. B. (2008). Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease. Ann. Intern. Med, 148(12), 939–955. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256736.
Lerner, L. J., Bianchi, A., Yiacas, E., & Borman, A. (1966). Effects of hydroxyurea and related compounds on the blood and marrow of experimental animals. Cancer research, 26(11 Part 1), 2292–2296. URL: https://cancerres.aacrjournals.org/content/26/11_Part_1/2292.
Margaretten, W., Morgan, C., Rosenkranz, H. S., & Rose, H. M. (1966). Effect of Hydroxyurea on Virus Development I. Electron Microscopic Study of the Effect on the Development of Bacteriophage T4. Journal of bacteriology, 91(2), 823–833. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC314936.
Nii, S., Rosenkranz, H. S., Morgan, C., & Rose, H. M. (1968). Electron microscopy of herpes simplex virus III. Effect of hydroxyurea. Journal of virology, 2(10), 1163–1171. URL: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC375449.
Osipov, A. S., Nechaeva, E. B., & Truhacheva, L. A (2016). Chromatographic column with nitrile sorbent used in the analysis of hydroxycarbamide by hydrophilic interaction liquid chromatography. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 3, 58–61 (in Russian).
Osipov, A. S., Popova, O. A., Larionova, S. G., & Ti-moshina, E. Yu, (2017). Hydrophylic interaction chromatography used for separation of hydroxycar-bamide and urea. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 7(2), 81–84 (in Russian).
Pongudom, S., Phinyo, P., Chinthammitr, Y., Charoenprasert, K., Kasyanan, H., Wongyai, K., ... & Surawong, A. (2020). Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial. Asian. Pacific. Journal of Cancer Prevention, 21(1), 147–155. doi: 10.31557/APJCP.2020.21.1.147.
Regan, S., Yang, X., Finnberg, N. K., El-Deiry, W. S., & Pu, J. J. (2019). Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. Cancer biology & therapy, 20(11), 1389–1397. doi: 10.1080/15384047.2019.1647055.
Romanyuk, Yu. P., Demchuk, O. G., & Melnik, A. N. (1986). Sravnitelnoe izuchenie immunodepressivnogo deystviya imohlena, osimochevinyi i imurana v ek-sperimente. Sb. ”Optimizatsiya lekarstvennogo obespecheniya i puti povyisheniya effektivnosti far-matsevticheskoy nauki”, Harkov (in Russian).
Rosenkranz, H. S., Rose, H. M., Morgan, C., & Hsu, K. C. (1966). The effect of hydroxyurea on virus devel-opment: II. Vaccinia virus. Virology, 28(4), 510–519. doi: 10.1016/0042-6822(66)90235-2.
Russell, E. (2009). Ware, Banu Aygun; Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program 2009, 1, 62–69. doi: 10.1182/asheducation-2009.1.62.
Rutschmann, O. T., Opravil, M., Iten, A., Malinverni, R., Vernazza, P. L., Bucher, H. C., & Perrin, L. H. (1998). A placebo-controlled trial of didanosine plus stavu-dine, with and without hydroxyurea, for HIV infec-tion. Aids, 12(8), 71–77. doi: 10.1097/00002030-199808000-00003.
Souza, S. S., dos Santosa, I. G., da Silvaa, C. V., & Laignier Cazedey, E. C. (2020). Qualitative Analysis of Hydroxyurea. Drug Anal. Res., 4(1), 18–21. doi: 10.22456/2527-2616.100682.
Schrell, U. M., Rittig, M. G., Anders, M., Kiesewetter, F., Marschalek, R., Koch, U. H., & Fahlbusch, R. (1997). Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. Journal of neurosurgery, 86(5), 845–852. doi: 10.3171/jns.1997.86.5.0840.
Sinclair, W. K. (1965). Hydroxyurea: differential lethal effects on cultured mammalian cells during the cell cycle. Science, 150(3704), 1729–1731. doi: 10.1126/science.150.3704.1729.
Singh, A., & Xu, Y. J. (2016). The Cell Killing Mechanisms of Hydroxyurea. Genes (Basel), 7(11), 99. doi: 10.3390/genes7110099.
Sivakumar, P., Meenakshi, S., Govindan, R. V., & Subba, Rao (2013). Spectrophotometric determination of hy-droxyurea and stability in nitric acid medium. Interna-tional Journal of Nuclear Energy Science and Engi-neering, 3(2), 27–31. URL: https://issuu.com/sep2011--now/docs/3_88872b3a1d3fbf.
Steinberg, M. H., Lu, Z. H., Barton, F. B., Terrin, M. L., Charache, S., & Dover, G. J. (1997). Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood Adv., Am. J. Hematol., 89(3), 1078–1088. URL: https://pubmed.ncbi.nlm.nih.gov/9028341.
Sverdlova, O. V. (1973). Elektronnyie spektryi v or-ganicheskoy himii. L.: Himiya (in Russian).
Tanzer, J., Jacquillat, C., Weil, M., Levy, D., Najean, Y., Boiron, M., & Bernard, J. (1966). Effects of hy-droxyurea in chronic myeloid leukemia. Preliminary study. La Presse medicale, 74(56), 2929–2930.
Thurman, W. G., Bloedow, C., Howe, C. D., Levin, W. C., Davis, P., Lane, M., Sullivan, M. P., & Griffith, K. M. (1963). A phase I study of hydroxyurea. Cancer Chemother. Rep., 29, 103–107. URL: https://pubmed.ncbi.nlm.nih.gov/13981319.
Veale, D., Cantwell, B. M. J., Kerr, N., Upfold, A., & Harris, A. L. (1988). Phase 1 study of high-dose hydroxyurea in lung cancer. Cancer Chemother Pharmacol, 21(1), 53–56. doi: 10.1007/BF00262739.
Vladzimirska, O. V., Soronovich, I. I., Rudiy, R. V., Hveschuk, L. G. (1984). Vivchennya novogo pro-tileykoznogo zasobu “oksisechovina” ta produktIv yiyi peretvorennya. Farmatsevtichniy zhurnal, 34–37 (in Ukrainian).
Vladzimirskaya, O. V., & Demchuk, O. G. (1974). Harak-ternyie reaktsii oksimochevinyi. Sb. “Vsesoyuznoe soveschanie po analiticheskomu kontrolyu proizvod-stva lekarstvennyih i farmatsevticheskih preparatov”, Perm, 1974, 113 (in Russian).
Vladzimirskaya, O. V., Turkevich, N. M., & Melnik, V. F. (1981). Tautomeriya protivoleykoznogo preparata – oksimochevinyi. Farmatsiya, 2, 17–19 (in Russian).
Ware, R. E., & Helms, R. W. (2012). Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood Adv., Am. J. Hematol., 119(17), 3925–3932. doi: 10.1182/blood-2011-11-392340.
Wilson, J. G., Scott, W. J., Ritter, E. J., & Fradkin, R. (1975). Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology, 11(2), 169–178. doi: 10.1002/ tera.1420110205.
Yadav, D. K., Paul, T., Alhamar, M., Inamdar, K., & Guo, Y. (2020) Pure erythroid leukemia in a sickle cell patient treated with hydroxyurea. Case Rep. Oncol., 13, 857–862. doi: 10.1159/000508361.
Abstract views: 105 PDF Downloads: 93